“tysabri” Archives

Entry Author Date Location
Harvard’s Springer Gets $51.5M From Pharmas, Others, For Latest Startup 06/30/16 Boston
West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More 12/23/14 San Francisco
Déjà Vu? Elan Alumni Start Antibody Firm to Fight Neurodegeneration 12/15/14 San Francisco
Ex-Elan Trio Grabs Their Former Employer’s Kinase Inhibitor Program 09/29/14 San Francisco
Immune Design Grabs $32.5M, Cashing in on Cancer Immunotherapy Rush 10/30/13 Seattle
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
Biogen Idec Wins FDA Approval For Oral Multiple Sclerosis Drug 03/27/13 Boston
Prothena of South San Francisco Gets Head Start as Elan Spinoff 01/09/13 San Francisco
Seattle Genetics Sees Case of PML, Causing Market Twitch 12/01/11 Seattle
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO 04/27/11 Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug 04/21/11 Boston
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb 04/11/11 Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy 03/02/11 Boston
Report: Layoffs Hit Elan 01/26/11 San Francisco
Biogen Aims to Reduce PML Risk 12/22/10 Boston
Biogen Idec Buys Drug Rights from Neurimmune for $32.5M 12/21/10 Boston
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan 11/04/10 Boston
Biogen Idec Offering Jobs to Quarter of San Diego Workers, While Most Get Layoff Notices 11/03/10 Boston
Biogen Idec Axes 650 Jobs, Closes San Diego Site, Bets Future on Neurology 11/03/10 Boston
Biogen Rival Reaches Finish Line with Oral Drug for MS 09/22/10 Boston
Arena Signs Deal With Eisai for Lorcaserin, Qualcomm CEO Identifies Two Opportunities in Mobile Health, & More San Diego Life Sciences News 07/08/10 San Diego
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve 07/01/10 Boston
Chairman Bill Young: Next Biogen Idec CEO May Be a Scientist 02/22/10 Boston
Tysabri’s PML Count Climbs to 28, and Some Reflections From Biogen Idec’s Departing CEO 01/06/10 Boston
Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism 01/04/10 Boston
Facet Rejects Biogen’s Latest Offer 12/10/09 Boston
Biogen Fattens Offer to Buy Facet Biotech 12/03/09 Boston
Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder 11/20/09 Boston
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore 11/19/09 Boston
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’ 10/23/09 Boston
Page 1 of 3 next page »